Cipla announces reentry into Chinese market with Jiangsu Acebright
Category: #healthcare  By Akshay Kedari  Date: 2019-07-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Cipla announces reentry into Chinese market with Jiangsu Acebright

The global pharmaceutical giant Cipla reportedly announced that it has reentered Chinese market in an alliance with Jiangsu Acebright. The company will set up a manufacturing plant for respiratory products in China under the joint venture.

According to reliable sources, both the companies will invest nearly $30 million for the joint venture mutually. Cipla EU, a wholly owned subsidiary of Cipla, will hold an 80 percent share and Acebright will hold a 20 percent share. Even though Cipla will start off with respiratory products in China, it has plans to expand to other segments in the future.  

Umang Vohra, MD & Global CEO, Cipla, reportedly stated that the company is keen to take its well-established knowhow in the respiratory sector to patients in China. Concurrently, the company will explore several means to build a portfolio of products in other therapeutic segments like oncology. Also, it will consider China as an important part of its future roadmap, he further added.

Shengping Xu, Chairman, Acebright Group, reportedly stated that the company has an established partnership of over 20 years with Cipla which shares its vision and approach towards patients.

Apparently, this is not the first time Cipla has entered the Chinese market. In 2012, the pharma major held stakes in three different Chinese companies, 48.2% in Jiangsu-based Cdymax, 16.6% in Shanghai Desano Pharmaceuticals and 25% in Biomab.

Reportedly, Cipla later rejigged its investments letting go of the stake in Cdymax and Biomab. It had sold its stake in Jiangsu-based Cdymax in 2014 for $18.5 million. The share in Hong Kong-based Biomab was sold in 2015 to British Virgin Islands-based Biomab Brilliant for $25.8 million.

Cipla share price has gained 0.54% or 3 points to 553.75 level in afternoon trade on BSE after the announcement. It has recently closed at 550.75 level in trade.

Source credit:

https://www.businesstoday.in/sectors/pharma/cipla-china-joint-venture-jiangsu-acebright/story/364719.html

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-forms-jv-with-jiangsu-acebright-for-respiratory-medicines-in-china/articleshow/70242041.cms?from=mdr

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Guangzhou Automobile investment in Nio will be capped at $150m
Guangzhou Automobile investment in Nio will be capped at $150m
By Akshay Kedari

Nio had indicated an urgent need to secure funds and early talks with Guangzhou Auto   ...

Moderna adds two candidates in new autoimmune therapeutic area
Moderna adds two candidates in new autoimmune therapeutic area
By Akshay Kedari

Moderna, Inc., a Cambridge, Massachusetts-based biotechnology firm that is focused on drug discovery...

Guardant and NRG Oncology initiate NRG-GI005 study in colon cancer
Guardant and NRG Oncology initiate NRG-GI005 study in colon cancer
By Akshay Kedari

Survival rate for stage II colon cancer is about 58 to 88% and patients will gain from additional tr...